India, June 18 -- Shares of Scholar Rock (SRRK) are up nearly 13% at $35.18 in premarket trading on Wednesday, following positive results from its EMBRAZE trial.
EMBRAZE is a phase II proof-of-concept trial evaluating the company's lead drug candidate Apitegromab in combination with Lilly's Zepbound, an approved GLP-1 receptor agonist, in patients with obesity or overweight.
Glucagon-like peptide-1 (GLP-1) therapies like Zepbound (tirzepatide) have been an effective and important innovation for individuals living with obesity and cardiometabolic disorders. However, they are associated with significant reductions in lean body mass, including muscle, leading to unwanted health risks.
The EMBRAZE trial has now demonstrated that Apitegromab ...